AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as ... the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab) – which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's Cinqaero ...

GlaxoSmithKline Pharmaceuticals Limited is ... 2021 Company launched the Nucala, first anti-IL5 drug, auto-injector device in India. It launched Trelegy Ellipta, the countrys first single inhaler ...

According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...

· Approval based on RUBY Part 1 trial, which showed a median overall survival (OS) of 44.6 months for Jemperli plus chemotherapy vs. 28.2 months for chemotherapy alone · Jemperli plus ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

News for GlaxoSmithKline Consumer Healthcare Ltd. Google.org Grants $1 Million to Karya for AI Upskilling in India Google.org awards USD 1 million to Karya, an Indian non-profit, to empower low-income ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Federal Workers Told to Inform on Colleagues Trying to Evade D.E.I. Crackdown Justice Department orders a halt to civil rights work. Budget nominee hints at work requirements for Medicaid. Local ...

Teva Pharmaceutical Industries Ltd. ADR-0.46% $24.97B ...